Aurigene Discovery Technologies Limited – Product Pipeline Review

Global Markets Direct’s, ‘Aurigene Discovery Technologies Limited – Product Pipeline Review – 2016’, provides an overview of the Aurigene Discovery Technologies Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Aurigene Discovery Technologies Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Aurigene Discovery Technologies Limited

The report provides overview of Aurigene Discovery Technologies Limited including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Aurigene Discovery Technologies Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Aurigene Discovery Technologies Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Aurigene Discovery Technologies Limited’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Aurigene Discovery Technologies Limited

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Aurigene Discovery Technologies Limited’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Aurigene Discovery Technologies Limited Snapshot 6

Aurigene Discovery Technologies Limited Overview 6

Key Information 6

Key Facts 6

Aurigene Discovery Technologies Limited - Research and Development Overview 7

Key Therapeutic Areas 7

Aurigene Discovery Technologies Limited - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products - Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

Aurigene Discovery Technologies Limited - Pipeline Products Glance 16

Aurigene Discovery Technologies Limited - Early Stage Pipeline Products 16

IND/CTA Filed Products/Combination Treatment Modalities 16

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Aurigene Discovery Technologies Limited - Drug Profiles 19

AUR-012 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Drugs to Target Fab Pathway for Gram Negative Bacterial Infections 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

AEA-16 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

AU-1702014 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

AU-4869 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

CA-170 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

CA-4948 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Drugs for Cancer 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Drugs to Inhibit EZH2 for Cancer 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule to Agonize ROR-Gamma for Inflammation and Oncology 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecules to Antagonize TIM-3 and PDL-1 for Oncology 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

AU-2439 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Drugs to Inhibit CDK9 and BET for Oncology 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Drugs to Inhibit MALT-1 for Oncology and Inflammation 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Drugs to Inhibit TDO and IDO for Oncology 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecule to Inhibit CDK7 for Oncology 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecule to Inhibit K-RAS for Oncology 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecules for Oncology 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Aurigene Discovery Technologies Limited - Pipeline Analysis 37

Aurigene Discovery Technologies Limited - Pipeline Products by Target 37

Aurigene Discovery Technologies Limited - Pipeline Products by Route of Administration 39

Aurigene Discovery Technologies Limited - Pipeline Products by Molecule Type 40

Aurigene Discovery Technologies Limited - Pipeline Products by Mechanism of Action 41

Aurigene Discovery Technologies Limited - Recent Pipeline Updates 43

Aurigene Discovery Technologies Limited - Dormant Projects 45

Aurigene Discovery Technologies Limited - Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Aurigene Discovery Technologies Limited, Key Information 6

Aurigene Discovery Technologies Limited, Key Facts 6

Aurigene Discovery Technologies Limited – Pipeline by Indication, 2016 8

Aurigene Discovery Technologies Limited – Pipeline by Stage of Development, 2016 10

Aurigene Discovery Technologies Limited – Monotherapy Products in Pipeline, 2016 11

Aurigene Discovery Technologies Limited – Partnered Products in Pipeline, 2016 12

Aurigene Discovery Technologies Limited – Partnered Products/ Combination Treatment Modalities, 2016 13

Aurigene Discovery Technologies Limited – Out-Licensed Products in Pipeline, 2016 14

Aurigene Discovery Technologies Limited – Out-Licensed Products/ Combination Treatment Modalities, 2016 15

Aurigene Discovery Technologies Limited – IND/CTA Filed, 2016 16

Aurigene Discovery Technologies Limited – Preclinical, 2016 17

Aurigene Discovery Technologies Limited – Discovery, 2016 18

Aurigene Discovery Technologies Limited – Pipeline by Target, 2016 38

Aurigene Discovery Technologies Limited – Pipeline by Route of Administration, 2016 39

Aurigene Discovery Technologies Limited – Pipeline by Molecule Type, 2016 40

Aurigene Discovery Technologies Limited – Pipeline Products by Mechanism of Action, 2016 42

Aurigene Discovery Technologies Limited – Recent Pipeline Updates, 2016 43

Aurigene Discovery Technologies Limited – Dormant Developmental Projects,2016 45

Aurigene Discovery Technologies Limited, Other Locations 46

Aurigene Discovery Technologies Limited, Subsidiaries 46

List of Figures

List of Figures

Aurigene Discovery Technologies Limited – Pipeline by Top 10 Indication, 2016 8

Aurigene Discovery Technologies Limited – Pipeline by Stage of Development, 2016 10

Aurigene Discovery Technologies Limited – Monotherapy Products in Pipeline, 2016 11

Aurigene Discovery Technologies Limited – Pipeline by Top 10 Target, 2016 37

Aurigene Discovery Technologies Limited – Pipeline by Molecule Type, 2016 40

Aurigene Discovery Technologies Limited – Pipeline Products by Top 10 Mechanism of Action, 2016 41

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports